Phase 1 Study of JV-213 for Relapsed or Refractory B-cell Lymphomas
This study is testing a new cell therapy called JV-213 for adults with B-cell lymphomas that have come back or not responded to previous treatments (relapsed or refractory). JV-213 is a type of CAR T-cell therapy, which uses your own immune cells to fight cancer. Researchers want to find the safest and highest dose of JV-213 that can be given. They will also look at how well JV-213 works to shrink tumors and improve symptoms. You would receive JV-213 through an IV after a procedure called leukapheresis, which collects your immune cells. The study is currently recruiting participants.
- Study design
- This is an interventional study planning to enroll 33 participants. It is designed to find the highest tolerable dose of JV-213.
- What's involved
- You would undergo leukapheresis to collect your cells, and then receive JV-213 through an IV. You will be monitored for side effects and tumor response.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be monitored for adverse events through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sattva Neelapu, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5through study completion; an average of 1 year